Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
PaperCitations, authors & open-access status
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 236 citations, 2023 year and hybrid oa status.
236
Citations
2023
Year
hybrid
OA Status